Investigational Studies

LONDON–(BUSINESS WIRE)– According to the latest research report released by Technavio, the global epilepsy drugs market is expected to grow steadily at a CAGR of more than 4% until 2020. This report titled ‘Global Epilepsy Drugs Market 2016-2020‘, provides an in-depth analysis of the market in terms of revenue and emerging trends. The report also […]

GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON, July 12, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it intends to sell, subject to market and other conditions, $150,000,000 of American […]

LONDON, July 12, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares (“ADSs”), representing […]

LONDON–(BUSINESS WIRE)–According to the latest research report released by Technavio, the global epilepsy drugs market is expected to grow steadily at a CAGR of more than 4% until 2020. This report titled ‘Global Epilepsy Drugs Market 2016-2020‘, provides an in-depth analysis of the market in terms of revenue and emerging trends. The report also considers […]

LONDON, July 12, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH), (GWP.L), (“GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 2,800,000 of American Depositary Shares (“ADSs”), representing […]

Stocks Analysts Ranking Summary: Fibrocell Science Inc (NASDAQ:FCSC) , GW Pharmaceuticals Plc (NASDAQ:GWPH) Fibrocell Science Inc (NASDAQ:FCSC) accumulated +33.01%, closing at $1.37 after floating between $1.05 and $1.59. The company has market capitalization of $60.14M. It has twelve month low of $0.91 and twelve month high of $7.60. The recent traded volume of 7.67 million shares […]

Following release in March of positive topline results from a phase 3 trial of an investigational cannabidiol product (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, GW Pharmaceuticals has now announced more positive results, this time from a phase 3 study in patients with Lennox-Gastaut syndrome (LGS). Like Dravet syndrome, LGS is a rare and […]

In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site. Medscape uses cookies to customize the site based on the information we collect at registration. The cookies contain no personally identifiable information and have no effect once you leave the Medscape site. … read more at: http://www.medscape.com/viewarticle/865452

GW Pharmaceuticals (NASDAQ:GWPH) edges up 3% premarket on light volume in response to its announcement that it has formalized a fourth target indication, infantile spasms (IS), for lead product candidate Epidiolex (cannabidiol). The FDA has designated Epidiolex an Orphan Drug for the treatment of IS. A two-part Phase 3 study should commence in Q4. IS is an […]

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS) – Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS –  – Phase 3 Trial Expected to Commence in Q4 2016 – LONDON, June 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or […]

– Orphan Drug Designation Granted from FDA for Epidiolex for the Treatment of IS –  – Phase 3 Trial Expected to Commence in Q4 2016 – LONDON, June 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its […]

[ACCESSWIRE] WINDSOR, ON / ACCESSWIRE / June 20, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to alert investors about a huge upcoming catalyst in the […]

GW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016 April 28, 2016 07:00 … read more at: https://globenewswire.com/news-release/2016/05/31/844629/0/en/GW-Pharmaceuticals-to-Present-at-the-Goldman-Sachs-37th-Annual-Global-Healthcare-Conference-and-the-Jefferies-2016-Healthcare-Conference.html